Nkarta, INC 10-Q quarterly reports

Nkarta, Inc. reported a net loss of $40.4 million for the second quarter of 2026, with operating expenses rising significantly, primarily driven by increased research and development costs.

Nkarta, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $27.8 million and continued investment in its lead CAR NK cell therapy candidate, NKX019, for autoimmune diseases.

Nkarta, Inc. reported a strategic pivot to focus on autoimmune disease therapies, reducing operating losses and detailing clinical progress for its lead candidate NKX019, while acknowledging ongoing capital needs.

Nkarta, Inc. reported continued net losses in Q2 2025, alongside a strategic pivot to prioritize autoimmune disease programs and a significant workforce reduction.

Nkarta, Inc. announces its Q1 2025 financial results, highlighting a net loss of $31.98 million and providing updates on its clinical development programs, including the addition of primary membranous nephropathy (pMN) as an indication to its Ntrust-1 clinical trial.

Nkarta, Inc. reported its third quarter 2024 financial results and announced a strategic shift to focus on autoimmune disease, deprioritizing its B-cell malignancy programs.

Nkarta Inc. reported its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Nkarta, a clinical-stage biopharmaceutical company, reported its first quarter 2024 financial results, highlighting a significant increase in cash and investments following a public offering.